Outcomes and Characteristics of Untreated Diffuse Large B-Cell Lymphoma (DLBCL) Patients: A SEER-Medicare Database Analysis

医学 弥漫性大B细胞淋巴瘤 四分位间距 内科学 化学免疫疗法 共病 队列 化疗方案 流行病学 儿科 外科 癌症 淋巴瘤 美罗华
作者
Akiva Diamond,Wyatt P. Bensken,Long Vu,Siran M. Koroukian,Paolo Fabrizio Caimi
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 10979-10980 被引量:3
标识
DOI:10.1182/blood-2022-170446
摘要

INTRODUCTION Diffuse Large B-cell Lymphoma (DLBCL) is most frequently diagnosed in the elderly, with a median age of presentation of 66 years. While approximately 60% of patients can achieve a cure with intensive anthracycline - based chemoimmunotherapy, treatment is associated with toxicity and may not always be safe in frail or elderly patients. Little is known about characteristics and outcomes in patients who are too frail for treatment or opt to not receive systemic therapy. METHODS: We used the Surveillance, Epidemiology, and End Results Program (SEER) linked with Medicare claims to identify 6,214 DLBCL patients (pts) diagnosed between 2007 and 2017. Data collected included demographic variables; comorbidity burden calculated using the Elixhauser comorbidity index with conditions present 30 to 365 days prior to DLBCL diagnosis. Initial therapy was defined as prescribed -30 to 100 days post-diagnosis. Patients who did not receive outpatient treatment but had current procedural terminology (CPT) codes reflecting inpatient chemotherapy were excluded from analysis. RESULTS: Of the 6,214 patients, 1,644 (26.5%) were untreated. Untreated patients were older with a median age of 81 years (interquartile range (IQR) 74-87) compared to 78 years old (IQR: 72-84) in the total cohort. Patients 85 years and older (≥85 y) represented 22.0% of the total cohort, 36.2% of untreated patients and 13.8% of patients receiving treatment for DLBCL. Overall, 43.6% of patients ≥85 y did not receive treatment. This percentage also varied by race: Of 194 black patients, 33% were not treated, compared to 26.4% of white patients. During the study period, 60.7% of the total cohort died. The proportion of deaths was higher in the untreated cohort (83.7%) and lower (45.4%) in the chemotherapy-treated cohort. Median survival of untreated patients was 3 months (IQR 2-27) . The median survival of the total cohort was 18 months (IQR 4-47). The comorbidity burden was higher in the untreated patients compared to both the total cohort and chemotherapy treated patients: 15% had congestive heart failure (CHF), 16.4% had peripheral vascular disease, and 10.8% had diabetes with complications. Table 1 lists selected Elixhauser comorbidities at time of diagnosis. Of 562 DLBCL patents with a diagnosis of CHF, 44.0% did not receive any treatment. CONCLUSIONS: Approximately one quarter of DLBCL patients in the SEER - Medicare database are listed as not receiving treatment. Untreated patients were older and had a higher burden of baseline comorbidities. Black patients were more likely to receive no treatment than white patients. Expectedly, untreated patients had short overall survival, highlighting the continued need for new tolerable therapies for DLBCL. Future analysis will focus on lymphoma specific mortality, time to event analyses and identification of populations at highest risk of not receiving therapy. These populations should be the target of research of novel therapeutic strategies in order to improve outcomes with minimized toxicity. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yan发布了新的文献求助10
刚刚
wryyyn完成签到,获得积分10
1秒前
风中孤晴完成签到 ,获得积分10
1秒前
兰心慧至完成签到,获得积分10
1秒前
2秒前
j7337完成签到,获得积分10
2秒前
DKH关闭了DKH的文献求助
2秒前
传奇3的应助被要减肥梦安采纳,获得10
2秒前
2秒前
Akim的应助被李优秀采纳,获得10
2秒前
tao发布了新的文献求助10
2秒前
3秒前
ZY发布了新的文献求助10
3秒前
嘻嘻哈哈的应助被打雷不下雨采纳,获得10
3秒前
ouoii完成签到,获得积分10
4秒前
找文献完成签到,获得积分10
4秒前
缥缈听白的应助被大饼采纳,获得10
4秒前
CHAosLoopy发布了新的文献求助10
4秒前
5秒前
笙笙发布了新的文献求助10
6秒前
bb完成签到,获得积分10
6秒前
6秒前
小二郎的应助被xd采纳,获得10
6秒前
6秒前
852的应助被Llh采纳,获得10
7秒前
7秒前
znznznzn1234完成签到,获得积分10
7秒前
顺利的莺发布了新的文献求助10
7秒前
7秒前
bonnie发布了新的文献求助10
7秒前
8秒前
科目三的应助被gogo采纳,获得10
8秒前
8秒前
张佳琪发布了新的文献求助10
8秒前
莎缇菈完成签到 ,获得积分10
8秒前
8秒前
8秒前
gegi完成签到,获得积分10
8秒前
鱼笙完成签到,获得积分10
8秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176481
求助须知:如何正确求助?哪些是违规求助? 9567855
关于积分的说明 21795109
捐赠科研通 7771163
什么是DOI,文献DOI怎么找? 3432027
关于科研通互助平台的介绍 2556365
邀请新用户注册赠送积分活动 2477695